| 19.58 -0.22 (-1.11%) | 08-13 13:22 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.56  |
1-year : | 28.95 |
| Resists | First : | 21.89 |
Second : | 24.79 |
| Pivot price | 19.8 |
|||
| Supports | First : | 17.2 | Second : | 14.31 |
| MAs | MA(5) : | 20.08 |
MA(20) : | 20.4 |
| MA(100) : | 21.18 |
MA(250) : | 19.58  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 55 |
D(3) : | 55.4 |
| RSI | RSI(14): 41.8 |
|||
| 52-week | High : | 25.59 | Low : | 12.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SNDX ] has closed above bottom band by 38.3%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.73 - 20.9 | 20.9 - 21.02 |
| Low: | 19.34 - 19.53 | 19.53 - 19.65 |
| Close: | 19.56 - 19.84 | 19.84 - 20.03 |
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Sun, 09 Aug 2026
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Sat, 08 Aug 2026
Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Fri, 07 Aug 2026
State Street Corporation (SNDX) discloses 5.66M-share, 6.4% holding in Syndax - Stock Titan
Fri, 07 Aug 2026
Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st
Wed, 05 Aug 2026
Syndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SNDX) 2026-08-05 - Seeking Alpha
Tue, 04 Aug 2026
Is Syndax Pharmaceuticals Inc (SNDX) Facing Value Challenges Aft - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 89 (M) |
| Shares Float | 80 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 120.8 (%) |
| Shares Short | 20,820 (K) |
| Shares Short P.Month | 19,860 (K) |
| EPS | -2.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.17 |
| Profit Margin | -87.6 % |
| Operating Margin | -55 % |
| Return on Assets (ttm) | -18.7 % |
| Return on Equity (ttm) | -256 % |
| Qtrly Rev. Growth | 91.8 % |
| Gross Profit (p.s.) | -0.23 |
| Sales Per Share | 2.82 |
| EBITDA (p.s.) | -2.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -221 (M) |
| Levered Free Cash Flow | -150 (M) |
| PE Ratio | -7.8 |
| PEG Ratio | 0 |
| Price to Book value | 115.02 |
| Price to Sales | 6.92 |
| Price to Cash Flow | -7.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|